☆ 4.7 Article

Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma

CLINICAL CHEMISTRY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis

Stefania Bunduc et al.

Summary: This systematic review and meta-analysis found that detectable cell-free DNA (cfDNA) biomarkers are associated with accelerated progression and decreased survival in pancreatic ductal adenocarcinoma (PDAC). The presence of circulant-tumor DNA (ctDNA) and KRAS mutations in cfDNA is linked to poorer overall and progression-free survival across various stages of PDAC. In cases where surgery is not feasible, the detection of ctDNA indicates a higher risk of disease progression, while the significance of KRAS mutations detection needs further investigation.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer

Silvia Waldeck et al.

Summary: The study revealed that intraoperative plasma sampling in early-stage and locally advanced NSCLC patients results in high ctDNA detection rates, and early postoperative ctDNA positivity serves as a prognostic indicator of disease relapse.

MOLECULAR ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer

Saskia Hussung et al.

Summary: Integrated analysis of plasma cfKRAS(mut) and CA 19-9 levels provides a promising approach for predicting disease course in patients with PDAC following resection. The dynamic monitoring using cfKRAS(mut) outperformed CA 19-9 in predicting early relapse and poor overall survival.

BMC CANCER (2021)

添加到收藏夹

Review Oncology

A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer

Deniz Can Guven et al.

Summary: Research suggests that ctDNA could be a promising tool in the early diagnosis of recurrences and tailoring treatment for pancreatic cancer patients, leading to improved survival outcomes.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Review Oncology

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review

Marisol Huerta et al.

Summary: Pancreatic cancer is a highly challenging and poor prognosis malignancy. Liquid biopsy using circulating tumor DNA (ctDNA) shows great potential as a non-invasive biomarker for early diagnosis, prognosis, and management of the disease, although its sensitivity remains limited and cannot be used as a screening or diagnostic tool.

CANCERS (2021)

添加到收藏夹

Article Cell Biology

Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer

Daniel W. Hagey et al.

Summary: This study focused on extracellular vesicles as an important source of tumor-derived DNA in liquid biopsies, and conducted experiments by collecting blood samples from 17 pancreatic cancer patients. The results showed that tumor-derived DNA was mainly present in LEVs and SEVs in the early stage of disease progression, and in SEVs and SP in the late stage of disease progression.

JOURNAL OF EXTRACELLULAR VESICLES (2021)

添加到收藏夹

Article Oncology

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Paul van der Leest et al.

Summary: Monitoring changes in circulating tumor DNA (ctDNA) levels can serve as a proxy for early tumor response to immunotherapy in metastasized non-small-cell lung cancer (NSCLC) patients, correlating with durable clinical benefit (DCB), progression-free survival (PFS), and overall survival (OS). Patients with a significant decrease (>30%) in ctDNA levels show longer PFS and OS, suggesting that ctDNA dynamics is a promising tool for assessing treatment outcomes in NSCLC patients receiving immune checkpoint inhibitors (ICI).

MOLECULAR ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer

Konstantin Schlick et al.

Summary: This study evaluated the feasibility of using cell-free tumor DNA with KRAS mutation in peripheral blood as a prognostic and predictive marker for chemotherapy monitoring in pancreatic cancer patients. The results showed that patients with detectable KRAS mutations in plasma had worse survival outcomes, and the dynamic assessment of KRAS mutation ratio was significantly associated with tumor response or progression.

PANCREATOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR

Irina Palacin-Aliana et al.

Summary: Cancer remains a major public health challenge worldwide, and molecular pathology profiling is fundamental for tumor diagnosis and therapeutic decisions. Liquid biopsies show potential as a tool for detecting cancer-specific biomarkers, providing information about tumor dynamics.

BIOMEDICINES (2021)

添加到收藏夹

Article Oncology

Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients

Shiwei Guo et al.

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer

Jiahong Jiang et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Pathology

Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing

Anne Macgregor-Das et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Application of liquid biopsy for surgical management of pancreatic cancer

Minako Nagai et al.

ANNALS OF GASTROENTEROLOGICAL SURGERY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Early Detection of Pancreatic Cancer: Opportunities and Challenges

Aatur D. Singhi et al.

GASTROENTEROLOGY (2019)

添加到收藏夹

Article Oncology

Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer

Vincent P. Groot et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer

B. Lee et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Liquid biopsies

Evi Lianidou et al.

GENES CHROMOSOMES & CANCER (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017

Shuji Isaji et al.

PANCREATOLOGY (2018)

添加到收藏夹

Article Oncology

Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer

S. Kruger et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients

He Cheng et al.

INTERNATIONAL JOURNAL OF CANCER (2017)

添加到收藏夹

Review Genetics & Heredity

Current and Emerging Applications of Droplet Digital PCR in Oncology

Susana Olmedillas-Lopez et al.

MOLECULAR DIAGNOSIS & THERAPY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer

Marzia Del Re et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Oncology

Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer

Sujuan Yang et al.

CANCER BIOLOGY & THERAPY (2017)

添加到收藏夹

Article Oncology

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

K. Allenson et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Review Oncology

Origins, structures, and functions of circulating DNA in oncology

A. R. Thierry et al.

CANCER AND METASTASIS REVIEWS (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

Mark Sausen et al.

NATURE COMMUNICATIONS (2015)

添加到收藏夹

Article Oncology

CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy

Werner Hartwig et al.

ANNALS OF SURGICAL ONCOLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

Jan Budczies et al.

PLOS ONE (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Simon A. Forbes et al.

NUCLEIC ACIDS RESEARCH (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma

Joshua G. Barton et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2009)

添加到收藏夹

Article Oncology

Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma

Cristina R. Ferrone et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

Article Surgery

Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey

D Dindo et al.

ANNALS OF SURGERY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.